Here's the latest on Viela Bio’s planned IPO
September 23, 2019 at 14:05 PM EDT
The planned IPO comes less than two years after the Gaithersburg biotech spun out of MedImmune, the former R&D division of AstraZeneca.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.